Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 15/20 | 0.47 |
| ▸ | EDNRB | P24530 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665085 | 0.76 | EDNRA (0.58) | EDNRAEDNRB | |
| SCHEMBL5213892 | 0.72 | EDNRA (0.47) | EDNRAEDNRB | |
| SCHEMBL5210933 | 0.72 | EDNRA (0.49) | EDNRAEDNRB | |
| SCHEMBL6152466 | 0.71 | EDNRA (0.48) | EDNRAEDNRB | |
| SCHEMBL6151140 | 0.70 | EDNRA (0.47) | EDNRAEDNRB | |
| SCHEMBL6151723 | 0.69 | EDNRA (0.48) | EDNRAEDNRB | |
| SCHEMBL6151572 | 0.69 | EDNRA (0.58) | EDNRAEDNRBMEN1CYP2C9TSHR | |
| SCHEMBL4630638 | 0.67 | EDNRA (0.54) | EDNRAEDNRB | |
| SCHEMBL6150865 | 0.67 | EDNRA (0.54) | EDNRAEDNRB | |
| SCHEMBL6151285 | 0.67 | EDNRA (0.60) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010021714-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC. | 2001-09-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021714-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | EDNRA, EDNRB, NPSR1 | EDNRA 1/4885EDNRB 2/4885MEN1 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.